Direct Thrombin Inhibitors: Appraisal of the Antithrombotic/ Hemorrhagic Balance

• References

• 1 Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing consideration, monitoring, efficacy, and safety. Chest 1995; 8 (Suppl): 259-275
• 2 Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884
• 3 Philippides GJ, Loscalzo J. Potential advantages of direct-acting thrombin inhibitors. Coron Art Dis 1996; 75: 497-507
• 4 Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS. et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 0993-1003
• 5 Chalapalli R, Lefkovits J, Topol EJ. Clinical trials of recombinant hirudin in acute coronary syndromes. Coron Art Dis 1996; 07: 429-437
• 6 Topol EJ, Fuster V, Harrington RA, Califf RM, Kleinman NS, Kereiakes DJ. et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1994; 89: 1557-1566
• 7 Antmann EM. for theTIMI-9A Investigators Hirudin in acute myocardial infarction: safety report form the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-1630
• 8 GUSTO Ha. Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1637
• 9 Neuhaus KL, van Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W. et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-1642
• 10 GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-782
• 11 Antmann EM. for the TIMI-9B Investigators Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-921
• 12 Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. Clin PharmTher 1995; 58: 123-126
• 13 Granger CB, Califf RM, Hirsh J, Woodlief LH, Topol EJ. for the GUSTO Investigators APTT’s after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age, and sex: experience from the GUSTO trial. Circulation 1992; 86: 11027 (Abstract)
• 14 Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of hirudin with heparin and warfarin with control for unstable angina and non Q wave MI in a randomized controlled trial. Circulation 1995; 92: 46 (Abstract)
• 15 Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster VE, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-2678
• 16 Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van deWerf F. for the GUSTO-2A Investigators Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995; 92 (Suppl. 01) 001-740 (Abstract)
• 17 Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol E. for the Hirudin in Unstable Angina Trial Circulation 1996; 94: 2389-2395
• 18 Gold HK, Torres FW, Garabedian HD, Werne W, Jang I, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-1047
• 19 Theroux P, Waters D, Lam J, Juneu M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-145
• 20 Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group . Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568
• 21 Granger CB, Meller JM, Bovill EG. et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91: 1929-1935
• 22 Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Stevens P, Weitz J, Maraganore J, Hirsh J. Effects on thrombin generation of single injections of hirulog™ in patients with calf vein thrombosis. Thromb Haemost 1994; 72: 523-525
• 23 Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-769
• 24 Serruys PW, Herrman JPR, Simon R, Rutsch W, Bode C, Laarman GJ. et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-763
• 25 Van de Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JJMM, Buller HR, Serruys PW. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88: 2058-2066
• 26 Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639
• 27 Eriksson BI. Recombinant hirudin, desirudin, (™REVASC) for prophylaxis of thromboembolic complications in patients undergoing total hip replacement. 14 International Congress of Thrombosis, Montpellier. 1996
• 28 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de BonoD, Ferguson J, Willerson JT, Stony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-1629
• 29 Ferguson JJ. Meeting highlights. American College of Cardiology 45^thAnnual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation 1996; 94: 1-5
• 30 Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwzrds P, Levine MN, Panju AA, Powers P, Stevens P, Turpie AGG, Weitz J, Buller HR, tnen CateJW, Neemeh J, Adelman B, Fox I, Maraganore J, Hirsh J. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-2389
• 31 Willerson JT, Casscells W. Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal. J Am Coll Cardiol 1993; 21: 1048-1051
• 32 Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Art Dis 1996; 7: 455-458
• 33 Herrman PR, Suryapranata H, den Heijer P, Kutryk MJB, Gabriël L, Serruys PW. Argatroban during percutaneous transluminal angioplasty; results of a dose verification study. J Thromb Thrombolysis 1996; 3: 367-375
• 34 Vermeer F, Vahanian A, Fels PW, Besse D, Radzik D, Simoons ML. Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction: preliminary results of the ARGAMI pilot study. J Am Coll Cardiol 1997; 29: 185-186 (Abstract)